Obstetricians and Gynecologists in Malaysia


Obstetricians-and-gynecologists in KL | Kuala Lumpur

 Obstetricians-and-gynecologists in PJ | Petaling Jaya

 Obstetricians-and-gynecologists in Johor

 Related terms for Obstetricians and Gynecologists in Malaysia:
Gynecologists, obstetrics, obstetrics and gynecology, obstetrics and gynaecology, obstetrics & gynaecology, gynaecology and obstetrics, obgyn, ob/gyn
Location: Malaysia

Comments

Post a Comment

Popular posts from this blog

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: November 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management.  The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regu...
Read more

GLP-1 Cost and Coverage 2026: Self-Pay, Insurance and Pill Prices

Image
By Dr. Frank Yap, MD  |  Last reviewed: November 2026  |  Purpose: evidence and cost education, not individual medical or financial advice Quick Answer In November 2026, advertised US self-pay prices for weight-management GLP-1s start at $149 per month (Wegovy pill 1.5 mg, Foundayo 0.8 mg) and run to $449 for higher-dose Zepbound KwikPen, down from list prices above $1,000. The White House announced the Eli Lilly and Novo Nordisk pricing agreements on November 6, 2025 and launched TrumpRx.gov on February 5, 2026; those announcements are the policy backdrop, but your price still depends on product, dose, insurance and offer expiry (several end December 31, 2026 ). Eligible Medicare patients may pay $50 per month through the GLP-1 Bridge (July 1, 2026 to December 31, 2027). This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are ...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Home › GLP-1 Hub > GLP-1 Muscle Loss By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The ...
Read more

GLP-1 and Beyond: What the Evidence Shows on Brain Health, Cancer Risk, Addiction and Next-Generation Drugs - Science Special Issue (2026)

Image
Quick Answer The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Observational data link these drugs to lower dementia risk in some metabolic populations, but large Alzheimer’s trials (EVOKE/EVOKE+) have not shown clinical benefit. Cancer-risk reductions appear largely tied to weight loss and related changes rather than proven intrinsic anticancer activity. Addiction research is promising but early. Key limitations include gastrointestinal effects, muscle loss, variable response, and weight regain after stopping. The issue stresses the need for better mechanistic studies, rigorous trials, and broader access strategies. Background: What the Special Issue Covers The package (introduction DOI: 10.1126/science.aen0869 ) includes three Reviews, two Perspectives, and a Policy...
Read more

Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options

Image
By Dr. Frank Yap, MD  |  Published: September 28, 2026  |  Last updated: October 2026  |  Reference: U.S. FDA labeling  |  Purpose: evidence and safety education, not individual medical advice Quick Answer In the U.S. in 2026, adult weight-management GLP-1 options include Wegovy (weekly injection), Wegovy HD 7.2 mg (weekly, only after 2.4 mg is tolerated for 4+ weeks), the Wegovy pill (daily), Zepbound (tirzepatide, weekly) and Foundayo (orforglipron, daily pill). The only direct head-to-head trial, SURMOUNT-5, found -20.2% weight loss with tirzepatide vs -13.7% with semaglutide at 72 weeks, but pills and injections should not be ranked across different trials. Pick by goal (weight, heart risk, sleep apnea, liver), route, tolerability and cost, protect muscle with protein and resistance training, and plan for long-term maintenance because weight re...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated November 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health wit...
Read more

Peptide Therapy in 2026: What the Evidence Says About BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon

Image
Updated:  November 2026 | Editorial team: OneDayMD | Purpose: Evidence and safety education Peptides are increasingly promoted for faster injury recovery, muscle growth, fat loss, better skin, improved sexual function, sleep and “anti-aging.” Some peptide medicines have transformed modern care. Others are experimental compounds with promising laboratory findings but little reliable evidence in people. The word peptide describes a type of molecule. It is not a guarantee of safety, effectiveness, purity or regulatory approval. Insulin and semaglutide are peptides; so are unapproved compounds sold online as “research chemicals.” Their evidence, manufacturing standards and medical uses are not interchangeable. Key takeaways Approved peptide medicines are not the same as research peptides. Approved medicines have been evaluated for specific uses, doses and risks. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon remain inves...
Read more

Healthy Lifestyle and Longevity (2026): The Evidence on Diet, Exercise, Supplements & Anti-Aging Drugs

Image
By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Originally published: August 24, 2026 | Last updated: October 2026 Quick Answer: A healthy lifestyle may add years to life, and potentially a decade or more in some populations, but no scientifically valid number applies to everyone. The biggest gains come from not smoking, regular physical activity, a high-quality diet, a healthy body weight, and controlled cardiovascular and metabolic risk factors . One influential U.S. analysis projected about 14 more years for women and 12 for men at age 50 for people with five low-risk habits versus none, but that is an observational estimate, not a guarantee. Supplements and anti-aging drugs are not proven to add a specific number of years. Preventing falls and injury also protects healthspan: balance and strength training is the best-supported strategy. In this guide What the Best Evidence Shows Other Studies Point the Same Way How Much Does Each Lifestyle Facto...
Read more

GLP-1 Clinical Trials & Research Tracker 2026

Semaglutide, tirzepatide, retatrutide, CagriSema, orforglipron and next-generation obesity medicines Research snapshot: 3 November 2026 · Curated Phase 3, pivotal and landmark human studies · Last editorial review: 3 November 2026 This tracker follows major clinical studies of GLP-1 receptor agonists and related incretin-based medicines across obesity, type 2 diabetes, cardiovascular disease, kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea and other obesity-related complications. It is designed as a research navigation tool: each entry links to its ClinicalTrials.gov record and, where available, a peer-reviewed paper, regulatory source or clearly identified sponsor announcement. The tracker distinguishes completed trials from posted results and distinguishes peer-reviewed evidence from sponsor-reported topline findings. How to use this tracker: Search by medicine, trial acronym, NCT number or condition. Use the dropdowns...
Read more

Top Peptide Protocols 2026: Best Stacks for Fat Loss, Recovery, Anti-Aging & Longevity

Image
By Dr. Frank Yap, MD  |  Originally published April 2026  |  Fully updated August 26, 2026 for the FDA's July 2026 compounding committee vote Quick Answer As of August 2026, GLP-1 receptor agonists (semaglutide, tirzepatide) remain the only peptides in this guide with full FDA approval. On July 23–24, 2026, an FDA advisory committee (PCAC) recommended adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the list of substances compounding pharmacies may use — but that vote is non-binding, and none of the six is lawful to compound yet; formal rulemaking is expected to take 12–24 months. Separately, AOD-9604 failed its pivotal human obesity trial back in 2007. The best human evidence among the non-GLP-1 peptides here belongs to topical GHK-Cu (skin) and Selank (anxiety); the weakest belongs to BPC-157 and TB-500 (mostly animal data). Any protocol should run through a licensed physician — not a gray-market vendor. Medical & regu...
Read more